The Net Margin of Zymeworks Inc. (ZYME) is
-76.56%.
Net Margin measures the percentage of net income derived from total revenue after all expenses. It signals how much actual profit a company retains from its sales.
| Date |
Value |
| 2025-12-31 |
-76.56%
|
| 2024-12-31 |
-160.80%
|
| 2023-12-31 |
-156.13%
|
| 2022-12-31 |
30.13%
|
| 2021-12-31 |
-793.26%
|
| 2020-12-31 |
-463.08%
|
| 2019-12-31 |
-492.88%
|
| 2018-12-31 |
-69.06%
|
| 2017-12-31 |
-20.08%
|
| 2016-12-31 |
-307.27%
|
| Ticker |
Name |
Value |
|
FMTX
|
Forma Therapeutics Holdings Inc
|
-34.59%
|
|
YMAB
|
Y-mAbs Therapeutics Inc
|
-33.83%
|
|
STOK
|
Stoke Therapeutics, Inc.
|
-3.73%
|
|
XENE
|
Xenon Pharmaceuticals Inc.
|
-4612.13%
|
|
KRYS
|
Krystal Biotech, Inc.
|
52.64%
|
|
NKTX
|
Nkarta, Inc.
|
-17566.67%
|
|
ARQT
|
Arcutis Biotherapeutics, Inc.
|
-4.29%
|
|
RPTX
|
Repare Therapeutics Inc
|
-158.95%
|
|
TH.TO
|
Theratechnologies Inc
|
-9.67%
|
|
FPRX
|
Five Prime Therapeutics Inc
|
-639.91%
|
|
KROS
|
Keros Therapeutics, Inc.
|
35.65%
|
|
SVA.V
|
Sernova Corp
|
-411.11%
|
|
ALVR
|
Allovir Inc
|
-14023.53%
|
|
KURA
|
Kura Oncology, Inc.
|
-412.95%
|
|
PAND
|
Pandion Therapeutics Inc
|
-2262.36%
|
|
KRON
|
Kronos Bio LLC
|
-874.08%
|
|
CYTK
|
Cytokinetics, Incorporated
|
-891.60%
|
|
GBIO
|
Generation Bio Co
|
-661.91%
|
|
OCGN
|
Ocugen, Inc.
|
-1537.41%
|
|
QURE
|
uniQure N.V.
|
-1236.00%
|
|
STTK
|
Shattuck Labs Inc
|
-4880.90%
|
|
VBIV
|
VBI Vaccines Inc
|
-1069.29%
|
|
APS.TO
|
Aptose Biosciences Inc
|
4175.00%
|
|
DMTK
|
DermTech Inc
|
-659.57%
|
|
NRIX
|
Nurix Therapeutics, Inc.
|
-314.90%
|
|
TRIL.TO
|
Trillium Therapeutics Inc
|
-39566.70%
|
|
ALEC
|
Alector, Inc.
|
-679.16%
|
|
CCCC
|
C4 Therapeutics, Inc.
|
-292.08%
|
|
FUSN
|
Fusion Pharmaceuticals Inc
|
-4588.83%
|